Key Points
- Director Carl Dambkowski sold 105,000 Oruka Therapeutics shares at an average price of $58.97, totaling about $6.19 million. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- Oruka Therapeutics recently reported a quarterly loss of $0.48 per share, which was better than analysts’ expectations of a $0.52 loss. Wall Street currently has a Moderate Buy consensus on the stock with an average price target of $120.80.
- The company is a clinical-stage biopharmaceutical firm focused on peptide-based cancer therapies, with its lead candidate ONCT-01 in Phase 1 trials for advanced solid tumors.
Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) Director Carl Dambkowski sold 105,000 shares of the firm's stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $58.97, for a total transaction of $6,191,850.00. Following the completion of the sale, the director owned 73,743 shares in the company, valued at $4,348,624.71. This represents a 58.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Oruka Therapeutics Stock Performance
NASDAQ:ORKA opened at $60.61 on Friday. Oruka Therapeutics, Inc. has a fifty-two week low of $10.64 and a fifty-two week high of $91.00. The stock has a market capitalization of $3.66 billion, a P/E ratio of -31.24 and a beta of -0.20. The company's 50-day simple moving average is $57.73 and its 200-day simple moving average is $40.43.
Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, beating analysts' consensus estimates of ($0.52) by $0.04. On average, research analysts forecast that Oruka Therapeutics, Inc. will post -2.05 EPS for the current year.
Analyst Upgrades and Downgrades
A number of analysts have recently weighed in on the stock. Wedbush set a $165.00 price target on shares of Oruka Therapeutics in a report on Monday, April 27th. Barclays raised their price target on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the company an "overweight" rating in a report on Monday, April 27th. UBS Group raised their price target on shares of Oruka Therapeutics from $75.00 to $100.00 and gave the company a "buy" rating in a report on Tuesday, April 28th. Leerink Partners set a $120.00 price target on shares of Oruka Therapeutics in a report on Thursday, April 30th. Finally, Wall Street Zen upgraded shares of Oruka Therapeutics from a "sell" rating to a "hold" rating in a report on Monday, March 16th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $120.80.
Read Our Latest Stock Report on Oruka Therapeutics
Institutional Trading of Oruka Therapeutics
A number of institutional investors have recently bought and sold shares of ORKA. Legal & General Group Plc acquired a new stake in Oruka Therapeutics in the 2nd quarter worth approximately $28,000. BNP Paribas Financial Markets boosted its stake in Oruka Therapeutics by 464.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company's stock worth $31,000 after purchasing an additional 2,306 shares in the last quarter. Royal Bank of Canada boosted its stake in Oruka Therapeutics by 47.2% in the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company's stock worth $34,000 after purchasing an additional 365 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in Oruka Therapeutics in the 4th quarter worth approximately $37,000. Finally, PNC Financial Services Group Inc. acquired a new stake in Oruka Therapeutics in the 3rd quarter worth approximately $39,000. 56.44% of the stock is currently owned by institutional investors and hedge funds.
About Oruka Therapeutics
(
Get Free Report)
Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”
The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
